Clinical trials: Platelet Function Disorder
Pre-Eclampsia, Hypertension
Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women
Whole blood sample procurement study from pregnant women with signs and symptoms of Preeclampsia.
- Conditions
- Pre-Eclampsia, Hypertension, Proteinuria in Pregnancy, Thrombocytopenia
- Trial name
- NCT03767803
- Testing
- Non-interventional study
- Where
- 24 sites in United States
- Volunteers
- 344 people
- Sponsor
- Progenity, Inc.
Healthy Subjects, Atherosclerosis
Effect Of Rilapladib (SB-659032) On Platelet Aggregation
The purpose of this study is to compare the effects of repeat doses of SB-659032 with placebo on platelet aggregation in subjects.
- Trial name
- NCT00387257
- Testing
- Rilapladib (SB-659032)
- Where
- Australia
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cardiovascular Diseases, Blood Pressure Disorders
Effect of Korean Red Ginseng Extract on Blood Flow in Healthy Adults
The objectives of this clinical trial are to 1) determine the effect of the TP compared to placebo on blood flow and platelet aggregation, 2) to determine the effect of the TP on cardiovascular health compared to a placebo and 3)…
- Conditions
- Cardiovascular Diseases, Blood Pressure Disorders, Vasodilation, Platelet Aggregation
- Trial name
- NCT06236243
- Testing
- Korean Red Ginseng Extract Powder 120 mg/tablet, Korean Red Ginseng Extract Powder 500 mg/tablet
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Korea Ginseng Corporation
Atherosclerosis
A Study to Assess the Effect of SB 659032 on Platelet Function
This will be an open-label, single dose, single period study. Approximately 14 subjects will receive one dose of 250 mg of non-enteric coated SB-659032 following a low-fat breakfast.
- Trial name
- NCT01750827
- Testing
- SB659032
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Coronary Arteriosclerosis, Acute Coronary Syndrome
GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety
The objective of the GRAVITAS trial is to determine whether tailored anti-platelet therapy using the Accumetrics VerifyNow P2Y12 assay reduces major adverse cardiovascular events after drug-eluting stent implantation.
- Trial name
- GRAVITAS (NCT00645918)
- Testing
- clopidogrel
- Where
- 82 sites in United States, Canada
- Volunteers
- 2,800 people
- Sponsor
- Accumetrics, Inc.
Congenital Heart Defects, Blood Platelet Disorders
Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)
PICOLO is a double blind placebo controlled phase II dose ranging, dose escalating study in patients of Blalock-Taussig age categories (neonates and infants/toddlers), to determine the dose providing inhibition of platelet…
- Trial name
- NCT00115375
- Testing
- Clopidogrel (SR25990)
- Where
- 6 sites in United States, Belgium and 4 more
- Volunteers
- 92 people
- Sponsor
- Sanofi
Stable Angina, Myocardial Infarction
Safety Evaluation of Clopidogrel Sulfate in Patients With Stable Angina/Old Myocardial Infarction to Whom Percutaneous Coronary Intervention is Being Planned
Primary objective: To evaluate whether 12 weeks of clopidogrel is superior to ticlopidine in terms of lower risk of the safety events of interest in patients with stable angina (SA) or old myocardial infarction (OMI) to which…
- Trial name
- CLEAN (NCT00821834)
- Testing
- clopidogrel (SR25990), ticlopidine
- Where
- Japan
- Volunteers
- 1,003 people
- Sponsor
- Sanofi
Acute Coronary Syndrome
A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome
The purpose of this study is to assess the safety and tolerability of E5555 in Japanese patients with acute coronary syndrome.
- Trial name
- NCT00619164
- Testing
- E5555
- Where
- 33 sites in Japan
- Volunteers
- 240 people
- Sponsor
- Eisai Co., Ltd.
Osteoarthritis of the Knee, Degenerative Osteoarthritis
Platelet-Rich Plasma and the Effects of NSAIDs on Pain and Functional Scores in Knee Osteoarthritis
The primary research purpose is to determine if the use of a drug therapy intervention (each study participant will be randomly assigned to receive one of 3 study medications which will be blinded from everyone, including the…
- Conditions
- Osteoarthritis of the Knee, Degenerative Osteoarthritis, Knee Pain Chronic
- Trial name
- PRPNSAIDsKOA (NCT05742763)
- Testing
- Ibuprofen and PRP, Acetaminophen and PRP
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- QC Kinetix LLC
Coronary Disease, Platelet Aggregation
VerifyNow® PRUTest® Cardiovascular Population Expected Values On-Drug Study
The purpose of this study is to determine the range of expected PRUTest values in patients in the intended use population receiving dual antiplatelet treatment with aspirin and prasugrel (Effient®), or ticagrelor (Brilinta®).
- Trial name
- NCT04492423
- Testing
- VerifyNow PRUTest
- Volunteers
- 100 people
- Sponsor
- Accriva Diagnostics
Arterial Obstructive Diseases, Coronary Disease
Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573)
The object of the study is to determine whether different doses of SCH 530348, when added to standard medical care in persons undergoing percutaneous coronary intervention, will increase the risk of bleeding.
- Trial name
- NCT00132912
- Testing
- SCH 530348
- Volunteers
- 1,030 people
- Sponsor
- Merck Sharp & Dohme LLC
Atherosclerosis
SB-659032 Platelet Aggregation Study
This study is designed to assess whether inhibition of plasma Lp-PLA2 activity impacts platelet function as assessed by ex vivo platelet aggregation tests and in vivo plasma biomarkers.
- Trial name
- NCT01745458
- Testing
- SB-659032
- Where
- Australia
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Stable Coronary Artery Disease
An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease
The purpose of the study is to determine the drug characteristics of Ticagrelor, and to determine if 4 weeks treatment will reduce the blood clotting.
- Trial name
- NCT01118325
- Testing
- ticagrelor, clopidogrel
- Where
- 13 sites in Japan, Philippines
- Volunteers
- 146 people
- Sponsor
- AstraZeneca
Seasonal Allergic Rhinitis
Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis
This Phase Ⅲ randomized, double-blind, active- and placebo-controlled trial aims to assess the efficacy and safety of Rupatifen Fumarate Capsules for seasonal allergic rhinitis.
- Trial name
- NCT07711262
- Testing
- Rupatifen Fumarate Capsules, Rupatadine Fumarate Tablets
- Where
- 18 sites in China
- Volunteers
- 550 people
- Sponsor
- Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.
Sickle Cell Disease
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
The purpose of the study is to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease
- Trial name
- HESTIA3 (NCT03615924)
- Testing
- Ticagrelor
- Where
- 55 sites in United States, Belgium and 14 more
- Volunteers
- 193 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease
The 5-milligram (mg) dose of prasugrel in low body weight (LBW) patients with coronary artery disease produces a pharmacodynamic response within the same therapeutic range as 10-mg dose in higher body weight (HBW) patients.
- Trial name
- FEATHER (NCT01107925)
- Testing
- prasugrel, clopidogrel
- Where
- 6 sites in United States, Ireland and 2 more
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Cerebral Infarction
Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment
The primary objective is to compare the safety of clopidogrel 50mg and 75mg in cerebral infarction with respect to incidence of bleeding adverse events.
- Trial name
- NCT00386191
- Testing
- clopidogrel (SR25990C)
- Where
- Japan
- Volunteers
- 1,110 people
- Sponsor
- Sanofi
Coronary Artery Disease
Prasugrel/Clopidogrel Maintenance Dose Washout Study
The primary objective of the study is to describe the cumulative proportion of participants who return to baseline platelet P2Y12 receptor function over time (up to 12 days post last maintenance dose) following discontinuation of…
- Trial name
- NCT01014624
- Testing
- Prasugrel, Clopidogrel
- Where
- 4 sites in United States
- Volunteers
- 56 people
- Sponsor
- Daiichi Sankyo
Cerebral Infarction
Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study
Sarpogrelate is an antiplatelet agent that decreases 5-hydroxytryptamine( 5-HT )levels in platelets via blockade of 5-HT2 receptors, has been used in atherosclerotic peripheral arterial disease.
- Trial name
- NCT00147303
- Testing
- MCI-9042
- Volunteers
- 46 people
- Sponsor
- Tanabe Pharma Corporation
COPD, Interstitial Lung Disease
An Observational Outcomes Study for Autologous Cell Therapy Among Patients With COPD and Interstitial Lung Disease
The purpose of the Lung Institute is to collect and isolate a patient's own cells and platelet rich plasma (PRP) and deliver the product back to the patient same-day.
- Trial name
- NCT03040674
- Testing
- Cell therapy
- Where
- United States
- Volunteers
- 489 people
- Sponsor
- Lung Institute